A new level of precision
Small molecule drugs can lack precision and their actual target may not be known, making them toxic. On the other hand, antibodies are very precise but typically lack potency.
Build precision into small molecules.
Centrose’s technology combines the potency of small molecule drugs with the precision of antibodies to place potent small molecule drugs angstroms from their desired site of action. This precision is unmatched in the industry, reducing off-target toxic side effects and increasing the drugs potency.
Today, drugs for life threatening diseases like cancer are extremely toxic and prone to resistance. This is because first line therapies target and kill all cells, even healthy ones and the more advanced “targeted” therapies can suffer from what is known as “drug resistance”.
In an effort to make potent therapies less prone to toxicity and resistance, Centrose created EDC Technology. EDC Technology exploits the fact that diseased cells construct unique and complex multi-protein structures on their surfaces. These structures include critical cell survival machinery, many of which were first observed at Centrose and are now being exploited to create a pipeline of drugs called EDCs.
Centrose’s first-line EDCs have been developed to kill cells by a process we call “targeted necrosis”. Necrosis is an alternative cell death pathway that has yet to be fully understood. Centrose believes that “targeted necrosis” could overcome cancer’s ability to become drug resistant and make tumors "hot", both important to those treating patients especially those prescribing immune checkpoint inhibitors such as Yervoy and Keytruda.
As reported in our cell press publication, Centrose discovered that drug targets were interacting with cancer markers. Along with this came the idea that antibodies could be used to deliver drugs with exquisite precision using EDC Technology. The EDCs described in the publication starve the cells for food, shut down their ability to transport nutrients and induce necrosis, offering completely new mechanisms for treating cancer.
LEAD and PIPELINE
Centrose's lead candidate is EDC9 which uses a generic Rituximab to target and kill CD20 positive cancers. EDC9 will initially be tested on patients with drug resistant Non-Hodgkin's Lymphomas (NHL). Centrose’s EDC1 kills metastatic cancers that express dysadherin, a protein that allows cancer cells to separate from tumor masses and spread throughout the body. Centrose’s EDC8 targets CD38 positive cells. CD38 forms protein complexes on the surface of Acute Myeloid Leukemia (AML) cells.